Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425543 | 0.96 | HPGD (0.66) | HPGDTSHRL3MBTL1NPC1ALKBH5 | |
| SCHEMBL7401505 | 0.95 | HPGD (0.69) | HPGDTSHRL3MBTL1NPC1ALKBH5 | |
| SCHEMBL4188852 | 0.84 | LMNA (0.50) | HPGDTSHRL3MBTL1NPC1ALDH1A1 | |
| SCHEMBL4725945 | 0.84 | L3MBTL1 (0.71) | HPGDTSHRL3MBTL1NPC1ALDH1A1 | |
| SCHEMBL8220304 | 0.83 | HPGD (0.46) | HPGDTSHRL3MBTL1NPC1ALDH1A1 | |
| SCHEMBL8898560 | 0.82 | POLB (0.55) | HPGDTSHRL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL12448379 | 0.79 | L3MBTL1 (0.49) | HPGDTSHRL3MBTL1NPC1ALDH1A1 | |
| SCHEMBL2933466 | 0.78 | HPGD (0.66) | HPGDTSHRL3MBTL1NPC1ALKBH5 | |
| SCHEMBL14489581 | 0.78 | L3MBTL1 (0.73) | HPGDTSHRL3MBTL1NPC1ALKBH5 | |
| Hydrazine SCHEMBL28119021 | 0.78 | TSHR (0.89) | HPGDTSHRNPC1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | HPGD 355/4885TSHR 562/4885L3MBTL1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.